Vilma Graupner

Roche (Switzerland) CH

Publications

1,120

Citations

H-Index

i10-Index

13.5

2yr Mean Cite

True

Cite/Paper

Data combined from OpenAlex . OA = OpenAlex S2 = Semantic Scholar

Verify on Google Scholar

Publication & Citation Trends

Publications

16 total

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial PDF

Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko, Daniil Stroyakovskiy, Delvys Rodríguez‐Abreu et al. - Journal of Thoracic Oncology, 2020

Cited by 597 OpenAlex

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko, Daniil Stroyakovskiy, Delvys Rodríguez‐Abreu et al. - Journal of Clinical Oncology, 2018

Cited by 220 OpenAlex

Research Topics

Cancer Immunotherapy and Biomarkers (11) Lung Cancer Treatments and Mutations (6) Lung Cancer Research Studies (5) CAR-T cell therapy research (4) Immunotherapy and Immune Responses (2)

Affiliations

Roche (Switzerland)

CH 2026 - 2018

External Profiles

OpenAlex Profile Search Semantic Scholar Google Scholar

Share Profile

Back to Researchers

Vilma Graupner

Publication & Citation Trends

Publications

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial PDF

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

Research Topics

Affiliations

External Profiles

Share Profile

Journal Details

Join JournalsHub

Welcome Back